Latest Personalized medicine Stories
AUSTIN, Texas, July 9, 2012 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced a definitive agreement to acquire privately-held, GenturaDx, a molecular diagnostics company focused on making nucleic acid testing both affordable and practical for any laboratory. GenturaDx is in late stage development of a fully integrated, highly automated, real-time PCR system that employs a single-use cassette for true sample-to-answer workflow. This new system will make rapid,...
IRVINE, Calif. and AMSTERDAM, July 9, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced a key addition to their executive team with the appointment of Glen Fredenberg as CFO and Vice President of Finance. "It is a very exciting time with the recent launch of Agendia's Symphony suite of tests in an FFPE format as well as the ColoPrint recurrence test for stage II colon cancer prognosis and prediction,"...
Lawrence LeBlond for redOrbit.com - Your Universe Online At least three genetic mutations found in the human brain have been linked to enlarged brain size (megalencephaly) and a number of disorders, including cancer, epilepsy and autism, according to new research led by Seattle Children’s Research Institute. The mutations were found in the genes AKT3, PIK3R2 and PIK3CA. The mutations were also linked to vascular disorders and skin growth disorders, said the researchers. The study,...
SAN DIEGO, June 28, 2012 /PRNewswire/ -- Millennium Laboratories, the leading research-based clinical diagnostic company dedicated to improving the lives of people suffering from pain, announced today the introduction of Millennium Pharmacogenetic Testing (PGT). Millennium PGT is saliva-based testing to detect genetic variations in enzymes associated with the metabolism of medications commonly prescribed to patients suffering from debilitating chronic pain and pain-related effects....
MANSFIELD, Mass., June 26, 2012 /PRNewswire/ -- PrimeraDx, a molecular diagnostics company, today announced that it has entered into a multi-year relationship with Eli Lilly and Company to develop diagnostic products in support of multiple clinical development programs for novel therapeutics. Under the terms of this agreement, the two companies will collaborate to develop innovative multiplex assays on PrimeraDx's clinical platform, the ICEPlex® System. Dr. Matt McManus,...
IRVING, Texas, June 26, 2012 /PRNewswire/-- Caris Life Sciences(®), a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, today announced the launch of Caris Target Now(TM) Select, an advanced, evidence-based molecular profiling service for patients with non-small cell lung cancer (NSCLC), melanoma, and cancers of the breast, colon and ovary. In addition, the company has enhanced the...
MOUNTAIN VIEW, Calif., June 26, 2012 /PRNewswire/ -- Based on its recent analysis of the clinical diagnostics market, Frost & Sullivan recognizes GenPath Diagnostics, a business unit of BioReference Laboratories, Inc. with the 2012 North American Frost & Sullivan Award for Company of the Year. As a BioReference specialized cancer laboratory, GenPath is a major factor to the Company's impressive growth trajectory--18 years of 20% Compound Annual Growth Rate...
LONDON, June 26, 2012 /PRNewswire/ -- Western Europe's greying population, coupled with the growing shift towards laboratory automation, are spelling good news for the in vitro diagnostics (IVD) market. New analysis from Frost & Sullivan (http://www.drugdiscovery.frost.com), Western European In Vitro Diagnostics (IVD) Market, finds that the market earned $13,110.3 million in 2011 and estimates this to reach $22,211.3 million in 2018 at a compound annual growth rate...
LONDON, June 26, 2012 /PRNewswire/ -- The Intellectual Property & Science division of Thomson Reuters released its annual synopsis of pharmaceutical industry trends today in its 2012 Pharmaceutical R&D Factbook, compiled by CMR International, a Thomson Reuters business. Key findings include the observation that the pharmaceutical industry's recent emphasis on quality over quantity is working, as evidenced by a lower number of early phase projects and fewer phase...
A new paper by Crislyn D'Souza-Schorey, professor of biological sciences at the University of Notre Dame, discusses the biology of tumor-derived microvesicles and their clinical application as circulating biomarkers. Microvesicles are membrane-bound sacs released by tumor cells and can be detected in the body fluids of cancer patients. The World Health Organization (WHO) estimates that the incidence of cancer will reach approximately 9 million deaths in 2015. The rising prevalence of the...
